Get the Stockscreener App
85.05
2.72%
-2.38
After Hours:
85.05
Henry Schein Inc stock is traded at $85.05, with a volume of 1.12M.
It is down -2.72% in the last 24 hours and down -3.90% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$87.43
Open:
$86.89
24h Volume:
1.12M
Relative Volume:
0.95
Market Cap:
$9.48B
Revenue:
$13.38B
Net Income/Loss:
$418.00M
P/E Ratio:
25.69
EPS:
3.3112
Net Cash Flow:
$391.00M
1W Performance:
-1.98%
1M Performance:
-3.90%
6M Performance:
+14.22%
1Y Performance:
+22.89%
1-Day Range:
$84.80
$87.98
1-Week Range:
$84.15
$87.98
52-Week Range:
$61.95
$92.18
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
85.05 | 9.74B | 13.38B | 418.00M | 391.00M | 3.3112 |
MCK
Mckesson Corp
|
880.50 | 103.91B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
312.28 | 60.00B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
221.27 | 51.42B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
0.7699 | 634.05M | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein stock heads into the open after a 0.47 percent drop - AD HOC NEWS
Henry Schein stock falls 2.72 percent despite higher guidance - AD HOC NEWS
Henry Schein Expands and Extends Revolving Credit Facility - The Globe and Mail
Henry Schein stock gains 0.42 percent ahead of the open - AD HOC NEWS
Henry Schein, Inc. Amends and Restates $1 Billion Revolving Credit Agreement to Increase Commitments to $1.25 Billion - marketscreener.com
Henry Schein stock gains as credit facility expands - AD HOC NEWS
Henry Schein Expands Revolving Credit Facility to $1.25 Billion - Minichart
Henry Schein Expands Revolving Credit Facility to $1.25 Billion, Extends Maturity to 2031 - TradingView
Henry Schein stock steady after recent earnings update - AD HOC NEWS
Henry Schein, Inc. (HSIC) Stock Analysis: A Promising 15.73% Upside in the Healthcare Sector - DirectorsTalk Interviews
Henry Schein stock heads into the open after a 0.3 percent dip - AD HOC NEWS
Henry Schein stock holds steady as investors eye latest earnings and valuations - AD HOC NEWS
Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher (NASDAQ:HSIC) - Seeking Alpha
Henry Schein (HSIC) Q1 2026 Earnings Call Transcript - Fortune
Henry Schein Prepares to Report Q2 Earnings: What's in the Cards? - Eastern Progress
Are Investors Undervaluing Henry Schein (HSIC) Right Now? - Yahoo Finance
Henry Schein stock heads into the open after a 1.99% drop - AD HOC NEWS
Henry Schein stock heads into the open after a 0.6 percent gain. - AD HOC NEWS
What Makes Henry Schein (HSIC) a New Buy Stock - Yahoo Finance
Henry Schein: Growth Is Improving, But The Valuation Stays Cheap (NASDAQ:HSIC) - Seeking Alpha
Henry Schein Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring an 11.12% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Henry Schein Inc Share PriceHSIC, RNS News, Articles, Quotes, & Charts (NASDAQ:HSIC) - Proactive financial news
Henry Schein stock holds firm after a fresh target lift - ad-hoc-news.de
Henry Schein stock heads into the open after a 1.0% daily loss - ad-hoc-news.de
Henry Schein Executive Andrea Albertini Reports Two Stock Disposals on September 8, 2026 - Kalkine Media
Tax withholding prompts Henry Schein (HSIC) insider to return shares - Stock Titan
Henry Schein stock holds steady after recent earnings update - ad-hoc-news.de
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
Precision Trading with Henry Schein Inc. (HSIC) Risk Zones - Stock Traders Daily
Henry Schein stock rises on a new distribution deal - ad-hoc-news.de
Henry Schein to Present at Baird Global Healthcare Conference - dentistrytoday.com
Henry Schein to Distribute Applied BioCode's MDx-3000 System in US - marketscreener.com
Applied BioCode Announces Distribution Agreement with Henry Schein - Business Wire
Henry Schein to Participate in Upcoming Investor Conference in September - Business Wire
How Investors May Respond To Henry Schein (HSIC) Distributing DermaSensor’s Skin Cancer Detection Device - webull.com
Henry Schein stock gains after strong Q2 2026 results and raised outlook - ad-hoc-news.de
Henry Schein, Inc. (HSIC) Stock Analysis: Unveiling a 9.33% Upside Opportunity in the Medical Distribution Sector - DirectorsTalk Interviews
Henry Schein stock gains institutional support as new diagnostic partnership advances strategy - AD HOC NEWS
Henry Schein Inc. helps children start the school year - Reading Eagle
Henry Schein stock rises after Q2 earnings beat - AD HOC NEWS
Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report? - Yahoo Finance
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein shares technical analysis: Resistance test at $92.68 in focus - Traders Union
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term - Eastern Progress
Is Henry Schein (HSIC) Stock Undervalued Right Now? - Yahoo Finance
Henry Schein (HSIC) Looks Modestly Undervalued, Is More Upside Still Available? - Yahoo Finance
Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis - Yahoo Finance
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 9.68% Upside Potential in the Medical Distribution Sector - DirectorsTalk Interviews
Henry Schein, Inc. (HSIC) Stock Report: Analyst Consensus Points to 10.95% Potential Upside - DirectorsTalk Interviews
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.03%
11.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):